initi coverag
ownership benefit initi overweight
invest summari initi coverag bsln stock
overweight rate price target think greater
appreci compani antifungal/antibiot commerci drug well
oncology-focus pipelin increas earn estim level yet reflect
consensu expect drive bsln share higher
ceftobiprol
underappreci
ceftobiprol safeti efficaci profil larg de-risk alreadi given
alreadi approv sale major eu countri sever non-
eu countri treatment adult patient cap hap exclud
two on-going cross-support phase studi requir nda file
acut bacteri skin skin structur infect absssi
complet expect erad staphylococcu aureu
bacteremia sab complet expect anti-mrsa hospit
antibiot market valu usd repres
global market certain brand daptomycin also basilea
barda contract partial fund phase program
usd total program cost ceftobiprol qidp
design extend market exclus year approv
sale upsid could come partner strategi product bsln
partner strategi commerci product cresemba zevtera/mabelio
underappreci view total usd total futur
potenti regulatori sale mileston licens agreement context
bsln report sale exchang rate dollar
almost bsln partner strong/larg pharmaceut compani
demonstr interest anti-infect like ow astella
cover partnership sustain durabl sourc cash
help support/fund bsln pipelin given cash burn
 get littl credit oncolog pipelin think investor
model littl revenu bsln oncolog pipelin strength
pipelin bolster target novel mechan action ex fgfr
inhibitor panraf/src kinas inhibitor opportun unmet need ex
glioblastoma icca expect see posit data/upd bsln
oncolog asset derazantinib next
 valuat use blend ev/ebitda dcf bull bear base case
analysi arriv price target
disclosur section may found page
initi coverag basilea pharmaceutica bsln ch
tabl content
product pipelin
partnership major
biopharmaceut compani develop product therapeut
area bacteri fungal infect cancer basilea two
cresemba isavuconazol compani pipelin includ three
kinas inhibitor tumor checkpoint control
panrab/src kinas inhibitor basilea found
headquart basel switzerland
dcf analysi result share price
assum wacc exit multipl exit multipl
use higher forward ev/ebit bsln peer
averag think deserv given upsid potenti
bsln pipelin versu competitor
invest thesi initi coverag bsln stock
overweight rate pt think greater
appreci compani antifungal/antibiot commerci
drug well oncology-focus pipelin increas earn
estim level yet reflect consensu expect
reason buy bsln stock
 market opportun ceftobiprol underappreci
expect upsid consensu sale expect come bsln
partner strategi commerci stage product
bsln get littl credit oncolog pipelin could drive
substanti upsid consensu sale expect view
clinic trial failur compound develop could advers
impact stock price
inabl achiev regulatori approv new product delay
regulatori approv could headwind futur sale growth
even product approv may meet sale
expect bsln and/or investor
compani cash burn neg free cash flow risk
ev/ebitda analysi result share price
ev/ebitda multipl higher forward ev/ebitda
bsln peer averag think deserv given
upsid potenti bsln pipelin versu competitor
bull- bear- base-cas analysi forecast likelihood
stock worth next month
bull-cas scenario arriv valu
assum better clinic trial success sale growth key drug
events/catalyst watch
phase interim analysi derazantinib
phase top-line data
phase absssi data ceftobiprol
think market opportun ceftobiprol underappreci
ceftobiprol cephalosporin antibiot iv administr alreadi approv sale
major european countri sever non-european countri treatment adult patient
community-acquir pneumonia cap hospital-acquir pneumonia hap exclud ventilator-
associ pneumonia vap market zevtera mabelio think de-risk factor
 opportun sinc drug clearli safe effect
 biggest market world-wide new brand hospit antibiot anti-mrsa hospit
antibiot market valu usd repres global market
certain brand daptomycin bsln two on-going cross-support phase studi requir
 nda file target acut bacteri skin skin structur infect absssi complet
expect erad staphylococcu aureu bacteremia sab complet expect
compani barda contract partial fund phase program usd
total program cost
ceftobiprol also qualifi infecti diseas product qidp design extend market
exclus year approv
expect upsid consensu sale expect come bsln partner strategi
total usd total futur potenti regulatori sale mileston licens
agreement cresemba zevtera/mabelio context bsln report sale
exchang rate dollar almost
think sustain durabl sourc cash help support/fund underappreci
bsln solid foundat sustain valu creation base implement partner
strategi cresemba isavuconazol zevtera/mabelio ceftobiprol compani commerci
strategi product optim valu via licens distribut agreement
lead pharmaceut compani onward bsln longer handl commerci
two product
compani expect sever addit launch europ region outsid europ
strong pharmaceut partner includ overweight astella cover
demonstr interest anti-infect juli announc start
compani reorgan key busi pfizer innov medicin busi includ new
hospit medicin busi unit commerci pfizer global portfolio steril inject
anti-infect medicin allow better focu custom centric
april licens partner asahi kasei pharma cover start phase studi japan
isavuconazol deep-seat mycosi expect studi complet
bsln get littl credit oncolog pipelin could drive substanti upsid consensu
believ investor model littl revenu bsln oncolog pipelin sale
drug could hundr million dollar context bsln report sale
exchang rate dollar almost
strength pipelin bolster target novel mechan action ex fgfr inhibitor
panraf/src kinas inhibitor opportun unmet need ex glioblastoma icca
compani three clinical-stag oncolog product pipelin
derazantinib potenti first-in-class oral panfgfr kinas inhibitor phase trial
intrahepat cholangiocarcinoma icca interim analysi expect
novel small-molecul microtubule-target agent mta use induc tumor cell
death checkpoint activ three on-going clinic studi
phase expans weekli iv patient w/ recurr glioblastoma platinum-
phase dose escal daili oral patient w/ recurr glioblastoma complet
phase studi daili oral combin w/ radiotherapi patient newli
diagnos glioblastoma collabor adult brain tumor consortium fund
 nation cancer institut estimate primari complet
oral dual-target panraf/src kinas inhibitor clinic phase test patient
divers solid tumor includ melanoma studi current analysi phase
includ biomark data result anticip publish futur scientif
would note three key potenti risk see rate price target bsln
clinic trial failur compound develop could advers impact stock price bsln
pipelin compound compani abl success advanc asset could
advers impact stock price product develop includ two phase trial
zevtera/mabelio ceftobiprol absssi sab well on-going studi oncolog
inabl achiev regulatori approv new product delay regulatori approv
could headwind futur sale growth bsln depend approv new product sustain
sale growth compani get new product approv sale growth moder
even declin time get new product regulatori bodi bsln want
commerci asset could also take longer resourc compani origin
even product approv may meet sale expect bsln and/or investor
bsln drug compet therapeut area incumb player
compani deeper pocket establish market platform bsln therefor even
bsln success get product approv sale expect could fall short compani
compani cash burn neg free cash flow risk
arriv pt bsln share use blend ev/ebitda dcf bull- bear- base-cas analysi
dcf analysi result share price assum wacc exit multipl exit multipl use higher
forward ev/ebit bsln peer averag think deserv given upsid potenti bsln pipelin versu
ev/ebitda analysi result share price ev/ebitda multipl higher forward ev/ebitda bsln peer
averag think deserv given upsid potenti bsln pipelin versu competitor
bull- bear- base-cas analysi forecast likelihood stock worth next month
exhibit bsln bull bear base case analysi
cantor fitzgerald research compani reportsbul caseposit phase absssi sab data ceftobiproleto support filingbett expect launch revenu growth cresembaand zevtera/mabelioprogress earlier stage oncolog scenario caseposit phase absssi sab data ceftobiproleto support filinglaunch revenu growth cresembaand zevtera/mabelioin-lin expectationsprogress earlier stage oncolog pipelin base-cas scenario potenti casephas absssi sab data ceftobiproledo support filingslow expect launch revenu growth cresembaand zevtera/mabeliofailur progress earlier stage oncolog scenario bsln valuat equiti compani compar
ev/ebitda analysi result share price ev/ebitda multipl higher forward ev/ebitda bsln peer averag
think deserv given upsid potenti bsln pipelin versu competitor
tickercompanypric cap mm debt/ ev/ ev/ price/ yield yield ep gr ratepeg ratio jone industri vector large-cap pharmabmybristol myer specialti large-cap factset cantor fitzgerald estim factset compani coverag mark ep estim adjust non-oper item debt/ebitda estim ebitda arithmet averag chang stock bsln upcom catalyst
next import catalyst bsln phase interim analysi derazantinib phase top-line data
weekli iv phase absssi data ceftobiprol
exhibit catalyst event calendar
datedriverupcom enrol phase dose-escal studi recurr glioblastoma daili phase dose-escal studi recurr glioblastoma daili panfgfr kinas inhibitor phase interim analysi intrahepat cholangiocarcinoma data phase expans weekli panfgfr kinas inhibitor initi phase develop fgfr-driven solid cancer ceftobiprol phase absssi data radiotherapyphas data newli diagnos glioblastoma daili ceftobiprol phase sab data isavuconazol complet phase studi japan deep mycosismid late ceftobiprol us launch absssi sab isavuconazol eu exclus end potenti pediatr exclus extens isavuconazol exclus endssourc cantor fitzgerald research compani report bsln compani histori
bsln found form spin-off entiti roch compani went public
swiss exchang recent event includ
januari initi phase studi combin radiotherapi patient newli
februari initi phase studi ceftobiprol absssi first two cross-support studi
requir nda market
april in-licens clinic oncolog drug candid derazantinib arqul cover exclus licens
world-wide exclud peopl republ china hong kong macau taiwan also in-licens preclin
select inhibitor kinas involv control cell divis
april licens partner asahi kasei pharma cover start pivot phase studi isavuconazol
japan treatment deep-seat mycosi compris invas aspergillosi chronic pulmonari aspergillosi
mucormycosi cryptococcosi
june progress phase extens patient recurr glioblastoma ovarian cancer
part bsln on-going phase clinic studi administ weekli iv infus
august initi phase erad studi ceftobiprol sab second two cross-support studi
requir nda market
cresemba launch germani franc uk itali austria spain nordic switzerland
greec ireland netherland
zevtera/mabelio launch itali franc germani uk austria switzerland spain nordic
argentina canada saudi arabia
bsln product pipelin overview
exhibit basilea product pipelin
isavuconazol market cresemba iv oral azol antifung treatment invas mold
infect isavuconazol approv commerci use follow territori
unit state approv treatment adult patient invas aspergillosi invas
eu approv treatment adult patient invas aspergillosi adult patient
mucormycosi amphotericin inappropri
switzerland approv treatment adult patient invas aspergillosi
treatment mucormycosi adult patient resist intoler amphotericin
adult patient moder sever renal impair
near-term strategi isavuconazol grow product revenu bsln signific
partnership japanes partner asahi kasei pharma respons bear cost develop
registr japan initi phase studi april territori
isavuconazol current approv bsln believ partner abl leverag exist
clinic data make submiss market author base exist product dossier
europ bsln expect see continu flow countri launch partner cours
next year
isavuconazol orphan drug design approv indic europ qidp
statu isavuzonazol exclus potenti pediatr exclus
extens eu
bsln industri overview competit landscap cresemba isavuconazol
death year attribut invas fungal infect cresemba strong
sale uptak initi key market increas contribut newer market reach
usd in-market sale month march
ceftobiprol market zevtera mabelio broad-spectrum iv gener cephalosporin
ceftobiprol approv major eu countri sever non-european countri
treatment adult patient community-acquir pneumonia cap hospital-acquir pneumonia
eu approv support two phase studi assess efficaci safeti first-lin empir
ceftobiprol versu singl combin drug compar treat hospit cap hap
compar studi cephalosporin antibiot combin anti-mrsa agent
involv mrsa suspect base posit studi result ceftobiprol demonstr
potenti replac dual therapi combin
double-blind random phase studi patient cap sever enough requir hospitalis multicent double-blind random phase studi patient includ vap patient arms-ceftobiprol medocaril infus everi hour day -ceftriaxon /- linezolid once-a-day infus /- linezolid infus everi hour day -ceftobiprol placebo infus everi hour placebo administ everi hour infus day -linezolid ceftazidim infus everi hour ceftazidim everi hour infus day primari outcomeclin cure rate test cure visit day last dose studi drugclin cure rate test cure toc visit day end-of-therapysecondari outcomemicrobiolog erad rate ratio number patient microbiolog erad total number patient microbiolog erad rate toc visit clinic cure rate late follow-up lfu visit defin day eot microbiolog erad rate lfu visit pneumonia-specif mortal rate within day random primari outcom resultsintent-to-treat analysi ceftobiprol vs compar ci evalu ce patient ceftobiprol vs compar ci ceftobiprol vs compar ci ce patient ceftobiprol vs compar ci rate hap exclud vap patient ceftobiprol vs compar ci rate hap exclud vap patient ce patient ceftobiprol vs compar ci outcom resultsmicrobiolog evalu patient ceftobiprol vs compar ci hap exclud vap patient patient ceftobiprol vs compar ci eventsoveral incid treatment-rel higher ceftobiprol group primarili owe differ rate self-limit nausea vs vomit vs compar ceftobiprol ceftazidime/linezolid septemb
phase absssi data expect
phase sab data expect
ceftobiprol seek approv largest market bsln initi two cross-support
phase studi requir nda file acut bacteri skin skin structur infect
think larg opportun sab associ signific morbid report
mortal rate accord compani drug approv treatment
approv drug requir week treatment rais concern develop resist
ceftobiprol qidp statu treatment community-acquir bacteri pneumonia cabp acut
bacteri skin skin structur infect absssi staphylococcu aureu bacteremia sab year
 market exclus upon approv
bsln enter barda contract partial fund phase develop ceftobiprol
support potenti regulatori file usd total program cost
ceftobiprol demonstr potent activ staphylococcu aureu post-hoc pool analysi
four double-blind random phase studi
exhibit preval aureu bacteraemia sab phase ceftobiprol trial
includ one patient mssa mrsa bacteraemia baselin
sourc pool analysi clinic cure mortal ceftobiprol medocaril versu compar staphylococc bacteraemia complic skin infect
community- hospit acquir pneumonia rello rahav scheeren saulay engelhardt welt oral present
post-hoc pool analysi clinic respons ceftobiprol similar standard-of-car
compar subgroup patient present sab
sourc pool analysi clinic cure mortal ceftobiprol medocaril versu compar staphylococc bacteraemia complic skin infect
community- hospit acquir pneumonia rello rahav scheeren saulay engelhardt welt oral present
analysi also indic trend toward lower mortal ceftobiprol versu compar
antibiot regimen subgroup patient present sab
sourc pool analysi clinic cure mortal ceftobiprol medocaril versu compar staphylococc bacteraemia complic skin infect
community- hospit acquir pneumonia rello rahav scheeren saulay engelhardt welt oral present
ceftobiprol treatment absssi support two previous conduct phase studi
demonstr potenti util ceftobiprol treatment bacteri skin infect trial
ceftobiprol studi treatment complic skin skin structur infect csssi
non-inferior condit met trial signific differ total
annal pharmacotherapi
analysi populationceftobiprol cure rate vancomycin cure rate ci differenceceftobiprol cure rate vancomycin/ceftazidim cure rate ci intent-to-treat gram-posit intent-to-treat gram-neg evalu gram-posit evalu gram-neg csssi trial csssi trial due csssi trial csssi trial industri overview competit landscap zevtera/mabelio ceftobiprol
accord bsln mrsa respons almost death caus antibiotic-
global anti-mrsa hospit antibiot market valu usd accord compani
 import region
cresemba zevtera/mabelio partnership major territori
bsln anti-infect portfolio synergist two commerci product hospit anti-
infect compani commerci strategi product optim valu via licens
distribut agreement lead pharmaceut compani onward bsln longer
handl commerci two product partnership cover countri partner
includ overweight astella cover
distribut agreement bsln remain respons manufactur product sell
product transfer price distribut partner bsln also elig receiv sale mileston
receiv up-front payment upon execut agreement
licens agreement bsln region partner respons commerci also
manufactur product bsln receiv up-front payment regulatori mileston
applic royalti sale mileston
total usd total futur potenti regulatori sale mileston licens
agreement cresemba zevtera/mabelio
cresemba zevtera/mabelio partnership major territori
exhibit current licens distribut agreement cresemba zevtera/mabelio
derazantinib formerli arq potenti first-in-class panfgfr kinas inhibitor bsln in-licens
arqul inc april term agreement arqul grant bsln right research
develop manufactur exclus commerci derazantinib world-wide exclud peopl
republ china taiwan hong kong macau bsln paid arqul up-front payment arqul
elig regulatori sale mileston payment upon reach certain clinic
regulatori commerci mileston well stagger single- double-digit royalti sale upon
derazantinib oral administ small-molecul inhibitor fgfr fibroblast growth factor
receptor famili kinas fgfr alter identifi potenti import therapeut
target variou cancer includ icca bladder breast gastric lung cancer accord bsln
current scientif literatur suggest fgfr alter exist rang cancer
derazantinib current registr phase trial intrahepat cholangiocarcinoma icca form
biliari tract cancer potenti acceler approv accord compani
drug demonstr favor clinic data biomarker-driven phase studi icca patient
interim analysi expect
fda ema grant arqul orphan drug design diseas
derazantinib also expect initi phase develop fgfr-driven solid cancer type
bsln develop potenti iv oral therapi address varieti differ cancer
novel small-molecul microtubule-target agent mta use induc tumor cell death
checkpoint activ bind colchicin site tubulin distinct effect
microtubul organ activ spindl assembl checkpoint promot tumor cell
death preclin studi demonstr vitro vivo activ divers
treatment-resist cancer model includ tumor resist convent approv therapeut
radiotherapi effici distribut brain anti-cancer activ glioblastoma model
prodrug
phase open-label dose-escal studi includ adult patient advanc solid tumor
fail standard therapi includ colorect gastric non-smal cell lung ovarian
pancreat triple-neg breast cancer twenty-four patient receiv two-hour iv
infus day treatment cycl well toler
drug-rel event includ inject site reaction nausea vomit diarrhea
peripher neuropathi mild moder well-manag transient hypertens dose-limit
event includ gait disturb peripher sensori neuropathi one patient confirm partial
respons last two year five patient show stabl diseas last four
month two patient addit post pre-treat tumor biopsi comparison demonstr
pronounc reduct tumor cell prolifer tumor vascular
bsln continu activ field glioblastoma common aggress form
primari malign brain tumor area high medic need treatment option
current avail three on-going clinic studi
phase expans weekli iv patient w/ recurr glioblastoma platinum-resist
phase dose escal daili oral patient w/ recurr glioblastoma complet
phase studi daili oral combin w/ radiotherapi patient newli diagnos
glioblastoma collabor adult brain tumor consortium fund nation cancer
bsln expect initi assess efficaci could becom avail
compani present press releas
oral dual-target panraf/src kinas inhibitor clinic phase test patient
divers solid tumor includ melanoma block braf craf kinas also
inhibit kinas famili play import role transmiss cell growth
prolifer signal melanoma aggress type skin cancer often link mutat braf
demonstr activ preclin studi rang patient-deriv melanoma model
intrins acquir resist select braf inhibitor well tumor model deriv
colorect pancreat lung cancer associ genet chang result activ raf
pathway target resist mechan associ approv braf
vemurafenib dabrafenib
compani develop licens agreement consortium organ includ
institut cancer research icr london cancer research technolog wellcom trust
univers manchest icr bsln partner licensor complet enrol first-in-human
phase dose-escal studi patient solid tumor includ metastat melanoma broad dose
rang investig studi maximum toler dose defin studi current
analysi phase includ biomark data result anticip publish futur scientif
bsln solid intellectu properti protect key asset includ isavuconazol
isavuconazol orphan drug design approv indic europ
qidp statu
isavuzonazol exclus
isavuzonazol potenti pediatr exclus extens eu
ceftobiprol qidp statu treatment
acut bacteri skin skin structur infect absssi
year market exclus upon approv
david veitch british citizen serv chief execut offic sinc april previous
serv chief commerci offic sinc septemb mr veitch serv presid
european oper savient pharmaceut acquir ow
serv senior vice presid european market brand
commerci bristol-my squibb pharmaceut cover
vice presid gener manag uk bristol-my prior
mr veitch held variou gener manag commerci role bristol-my squibb
pharmaceut prior smithklin beecham pharmaceut cover mr
veitch receiv sc biolog univers bristol uk
dr marc engelhardt german citizen serv chief medic offic sinc januari
succe prof achim kaufhold retir decemb dr engelhardt join bsln
head clinic research promot head develop
role dr engelhardt led bsln clinic research develop group act prof
kaufhold deputi prior join bsln dr engelhardt serv global program medic
director novarti pharma ag cover basel held variou posit
increas respons bracco-altana cover konstanz germani bracco
diagnost princeton nj usa cover dr engelhardt hold medic degre phd
univers frankfurt/main germani board certifi intern medicin
dr gerrit hauck german citizen serv chief technolog offic sinc may join
bsln sanofi cover cluster head synthet molecul sinc januari
role overse compani technic develop program
synthet molecul pre-clin candid launch sinc januari member
sanofi research stage gate committe respons transit candid
molecul research develop year experi variou
technic oper manag function sanofi predecessor compani
involv formul develop plant manag global leadership dr hauck
graduat pharmacist univers heidelberg germani hold phd
adesh kaul swiss citizen serv chief corpor develop offic effect march
previous serv head corpor develop sinc march
mr kaul serv bsln head busi develop licens investor relat
head public relat corpor commun held posit
cfo head corpor develop polyphor ag cover mr
kaul senior financi analyst neue zrcher bank cover held sever senior
execut posit gener manag sale market
genedata ag basel switzerland cover mr kaul hold master degre
biochemistri econom univers basel execut hsg st
dr laurenz kellenberg swiss citizen serv chief scientif offic sinc
dr kellenberg held role increas respons bsln serv head
chemistri member research manag team
respons key project lead find optim preclin
develop receiv phd continu scientif research univers
cambridg uk hoffmann-la roch basel cover held differ
posit preclin research chemic technolog join bsln
author numer scientif public hold phd organ chemistri swiss
feder institut technolog zurich zrich
donato spota italian german citizen serv chief offic sinc novemb
mr spota held variou posit bsln sinc join compani includ
global head financ servic head global control prior join bsln mr
spota held posit financi plan control hoffmann-la roch basel
cover area pharma global informat mr spota degre inform
technolog swiss bbt bundesamt fr berufsbildung und technologi hold
master degre busi administr univers appli scienc nrtingen
basileacantor chf mm except per share amount guidancemidpointestimatetot cresemba cantor fitzgerald research compani reportsto higher cash burn fy basilea expect slow cash burn overal compani expect cash burn averag per one-tim event like in-licens derazantinib pre-clin asset increas work capit basilea expect fy cash burn bsln model incom statement analysi
chf million compound-annual-growth-rate year end decemb oper incom share chang yoytot cantor fitzgerald research compani assum tax rate upon profit bsln model margin analysi
cantor fitzgerald research compani report bsln model half year sale analysi
chf million year end decemb chang yoyproduct cantor fitzgerald research compani report bsln model annual sale analysi
chf cantor fitzgerald research compani reportsyear end decemb bsln model analysi
chf million year end decemb flow provid oper activ net depreci net chang work net cash provid oper flow invest activitiespay short-term matur short-term payment long-term investments- purchas net proce sale acquisit net cash acquired- net cash use invest flow financ activ repay issuanc long term proce issuanc stock- net cash use provid financ effect exchang rate chang cash cash net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report bsln model balanc sheet analysi
chf million year end decemb account current total current plant properti equip tangibl asset identifi goodwill- total total liabil sharehold equityaccount total current long term debt total sharehold total stockhold non-controlling interest- total liabil stockhold sourc cantor fitzgerald research compani report bsln model market model
currenc swiss cresemba licens agreement pfizercas invas invas share share patient patient cost per patient ia swiss cost per patient im swiss sale revenu mileston sale china revenu mileston revenu revenu agreement astellascas invas invas share share patient patient cost per patient cost per patient agreement unimediccas invas invas share share patient patient cost per patient ia swiss cost per patient im swiss agreement asahi kasei pharmacas invas invas share share patient patient cost per patient ia swiss cost per patient im swiss distribut licens agreement grupo latin america mileston cresemba revenu cantor fitzgerald research compani reportsyear end decemb bsln model market model
currenc swiss zevtera/mabelio eu ex nordic israeldistribut agreement correviohospital-acquir pneumonia hap annual non-ventil hap nv-hap nv-hap annual zevtera/mabelio per day price treatment cost per basilea revenue/tot zevtera/mabelio us marketacut bacteri skin skin structur infect absssi market share patient per day price treatment durat total cost per absssi aureu bacteremia sab market share patient per day price treatment per sab ceftobiprol cantor fitzgerald research compani reportsyear end decemb septemb
basilea commerci stage biopharmaceut compani develop product therapeut area bacteri fungal infect
cancer basilea two commerci anti-infect product zevtera/mabelio ceftobiprol cresemba isavuconazol
tumor checkpoint control panrab/src kinas inhibitor basilea found headquart basel
